ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: OSI-027 has been shown to inhibit the growth of imatinib-resistant CML cells which contain the BCR-ABL T315I mutation that are resistant to all BCR-ABL inhibitors [270].